Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Capital Expenditures data on file, last reported at $8000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $322000.0, a 28.8% increase from a year earlier, with the FY2025 full-year figure at $314000.0, up 12.95% from the prior year.
• Capital Expenditures for Q1 2026 stood at $8000.0, down from $159000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for FULC reached as high as $508000.0 in Q4 2023 and fell as low as -$131000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $75600.0 across 5 years, with a median of $28000.0 in 2024.
• Across the five-year window, Capital Expenditures plunged 111.54% in 2022 and surged 8366.67% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $6000.0 in 2022, then jumped by 8366.67% to $508000.0 in 2023, then sank by 54.53% to $231000.0 in 2024, then slumped by 31.17% to $159000.0 in 2025, then slumped by 94.97% to $8000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $8000.0 in Q1 2026, $159000.0 in Q4 2025, and $155000.0 in Q3 2025.